Novartis Venture Funds

We concentrate on creating new therapeutics and platforms. We evaluate unmet clinical need, new proprietary science, understanding of mechanism and management experience. Capital Efficiency is a crucial consideration for investment. NVF invests as an equity investor in Biotechnology/Biopharma life sciences companies. The NVF function as the lead or co-lead investor in seed and later-stage investments. We contribute actively to company boards. We have an investment strategy that is stage-agnostic, which means we invest in all areas of therapeutic research that offer clear unmet medical needs. We first evaluate all non-confidential information about the company and team. NVF also examines financial, exit, technological, data, financial, and technical plans. The business proposal evaluation is based on a confidential presentation by management. This is the start of the complete due diligence. Because it includes the total process. The Novartis Venture Fund invests as an equity participation, normally as the syndicate’s lead investor or co-lead investor with a board seat.